Diabetes medications with cardiovascular protection - What now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?

Robert Ej Ryder, Ralph A. DeFronzo

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Diabetes medications with cardiovascular protection - What now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?'. Together they form a unique fingerprint.